Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

Table 2 Univariable analysis of risk factors for total VTE of 29 patients

Variable	No. of patients		(%)	OR	(95% CI)	P
Sex and age (yr.)
< 70	17	/64	27	1.0	(ref.)
≥ 70 male	4	/19	21	0.7	(0.2–2.5)	0.77
≥ 70 female	8	/14	57	3.7	(1.1–12.2)^a	0.054
BMI
< 25	21	/74	28	1.0	(ref.)
≥ 25	8	/23	35	1.4	(0.5–3.6)	0.75
Reduced mobility^b
No	22	/87	25	1.0	(ref.)
Yes	7	/10	70	6.9	(1.6–29.0)^a	0.007^*
Previous chemotherapy
No	24	/78	31	1.0	(ref.)
Yes	5	/19	26	0.8	(0.3–2.5)	0.92
Time from tumor onset (mo.)
< 6 or >12	23	/85	27	1.0	(ref.)
6–12	6	/12	50	2.7	(0.8–9.2)	0.17
Central venous access device
No	1	/ 7	14	1.0	(ref.)
Yes	28	/90	31	2.7	(0.3–23.6)	0.67
Using anti-VEGF antibody
No	26	/80	33	1.0	(ref.)
Yes	3	/17	18	0.5	(0.1–1.7)	0.26
Distant metastases
No	7	/32	22	1.0	(ref.)
Yes	22	/65	34	1.8	(0.7–4.9)	0.33
Developing acute infection^c
No	18	/67	27	1.0	(ref.)
Yes	11	/30	37	1.6	(0.6–3.9)	0.46
Platelet count (/μL)^d
< 350,000	25	/87	29	1.0	(ref.)
≥ 350,000	4	/10	40	1.7	(0.4–6.4)	0.48
Hemoglobin (g/dL)^d
≥ 10	26	/84	31	1.0	(ref.)
< 10	3	/13	23	0.7	(0.2–2.6)	0.75
Leukocyte count (/μL)^d
< 11,000	29	/93	31	1.0	(ref.)
≥ 11,000	0	/ 4	0	0.2	(0.0–4.7)	0.31
D-dimer (μg/mL)^de
< 1.5	7	/36	19	1.0	(ref.)
≥ 1.5	19	/58	33	2.0	(0.8–5.4)	0.24
TAT (ng/mL)^de
< 2.1	10	/50	20	1.0	(ref.)
≥ 2.1	16	/44	36	2.3	(0.9–5.8)	0.12
PIC (μg/mL)^{d, e}
≥ 1.8	7	/21	33	1.0	(ref.)
< 1.8	19	/73	26	0.7	(0.2–2.0)	0.70
TAT ≥2.1 ng/mL and PIC <1.8 μg/mL^{d, e}
No	14	/65	22	1.0	(ref.)
Yes	12	/29	41	2.6	(1.0–6.6)	0.082

VTE venous thromboembolism, OR odds ratio, CI confidence interval, BMI body mass index, VEGF vascular endothelial cell growth factor, TAT thrombin-antithrombin complex, PIC plasmin α2-plasmin inhibitor complex
^* P < 0.05. ^a95% CI over 1.0. ^bBedrest with bathroom privileges for at least three days at baseline, either due to patient’s limitation or on physician’s order. ^cDuring the three-month observation period. ^dMeasured at baseline, just before the first cycle of chemotherapy. ^eUnmeasured in three patients

ISSN: 1471-2407